Sfoglia per AUTORE
DIRAL E
Collezione ASL Biella

  

Items : 2

Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts. in American journal of hematology / Am J Hematol. 2023 Aug;98(8):E204-E208. doi: 10.1002/ajh.26960. Epub 2023 May 24.

2023
ASL Città di Torino
ASL Torino 4
AO Cuneo
ASL Biella
AO Ordine Mauriziano
AOU Città della Salute di Torino
AOU Novara
AOU Alessandria

Della Porta MG; Naldi I; Santini V; Turrini M; Giordano L; Finelli C; Pasini P; Tosi P; Tanasi I; Selleri C; Frigeni M; Sancetta R; Norata M; Marchetti M; Grimaldi D; Fianchi L; Galimberti S; Ferrara F; Di Veroli A; Di Bona E; Occhini U; Rivoli G; Bono R; Calvisi A; Castelli A; Nicolino B; Leuzzi L; Molteni A; Guarini A; et alii...

Efficacy and Safety of Luspatercept in Adult Patients with Transfusion-Dependent Anemia Due to Very Low, Low and Intermediate Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts, Who Had an Unsatisfactory Response to or Are Ineligible for Erythropoietin-Based Therapy: A Retrospective Multicenter Study By Fondazione Italiana Sindromi Mielodisplastiche (FiSiM ETS) in Blood

2022
ASL Biella
ASL Torino 4

Lanino L; Salutari P; Perego A; Fattizzo B; Riva M; Ubezio M; Musto P; Cilloni D; Oliva EN; Voso MT; Pelizzari AM; Poloni A; Capodanno I; Elena C; Fozza C; Pane F; Breccia M; De Gobbi M; Di Bassiano F; Barraco D; Crisà E; Ferrero D; Frairia C; Vaccarino A; Griguolo D; Paolini S; Quintini M; Sessa M; Turrini M; et alii...